Cagrilintid · DOSSIER

Cagrilintid

Cagrilintide · AM833
LEGAL DE · NOT APPROVEDEVIDENCE · EARLY CLINICAL STUDIES2 STUDIES
FIG.01 — SIGNAL CHAIN
02

Mechanism of action

What Cagrilintid does in the body — step by step.

01

Cagrilintide is a long-acting analog of the hormone amylin, which is co-secreted with insulin by the beta cells of the pancreas.

02

It acts at amylin and calcitonin receptors and influences satiety, gastric emptying and food intake.

03

Cagrilintide is investigated primarily in combination with the GLP-1 analog semaglutide (the "CagriSema" combination) to achieve additive effects on body weight.

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
Cagrilintide is in clinical development (Novo Nordisk).
Cagrilintide is in clinical development (Novo Nordisk).
A Phase 1b study (2021) investigated co-administration of cagrilintide with semaglutide and observed enhanced weight reduction versus semaglutide alone.
A 2025 study of the combination (CagriSema) in overweight and obesity confirmed substantial effects.
Phase III studies (the REDEFINE programme) are ongoing; there is no standalone approval of cagrilintide to date.
04

Known risks

Without human data, safety statements are limited. What is known:

01
Safety profile not conclusively established — no completed Phase III data
02
Gastrointestinal side effects (nausea, vomiting) frequently described
03
Injection-site reactions possible
04
Interactions and long-term effects not fully characterised
05
No long-term safety data available
05

Cited studies

Chronological — links lead to the source.

2021
Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial
PubMed 33894838 →
2025
Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity
PubMed 40544433 →
06

Frequently asked questions

What is Cagrilintid?+

Cagrilintide is a long-acting analog of the hormone amylin, which is co-secreted with insulin by the beta cells of the pancreas.

What type of peptide is Cagrilintid?+

Cagrilintid belongs to the Amylin analog class.

What is Cagrilintid used for?+

In research, Cagrilintid has primarily been investigated in the context of: Metabolism. These are research findings (evidence: early clinical studies), not proven benefits in humans and not a usage recommendation.

Is Cagrilintid legal in Germany?+

Cagrilintid is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.

Is Cagrilintid FDA-approved / legal in the US?+

No. Cagrilintid is not FDA-approved as a drug in the US; it is mostly sold as a research chemical and not for human consumption.

Is Cagrilintid legal in Canada?+

No. Cagrilintid is not authorized by Health Canada and not intended for human consumption.

Where can I buy Cagrilintid?+

Peptica sells nothing and names no sources. Cagrilintid is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of Cagrilintid?+

Peptica publishes no dosing. There are no approved dosing guidelines for Cagrilintid; figures circulating online stem from animal studies or anecdote, not from validated human protocols. This is not medical advice.

Is Cagrilintid banned in sport (WADA)?+

Cagrilintid is currently not on the WADA Prohibited List.

What are the known risks of Cagrilintid?+

Documented risks include: Safety profile not conclusively established — no completed Phase III data; Gastrointestinal side effects (nausea, vomiting) frequently described. This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is Cagrilintid?+

The evidence is classified as “early clinical studies”. 2 studies are cited on this page.

What is the molecular weight of Cagrilintid?+

Cagrilintid has a molar mass of about 4409 Da, with a plasma half-life of ~7–8 days (once weekly).

Which peptides are related to Cagrilintid?+

Closely related entries: Retatrutid, Tirzepatid, Semaglutid. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanynot approved

Cagrilintide does not yet have market approval and is investigated mainly in combination with semaglutide in Phase III studies. Obtaining it as a research chemical outside clinical studies is illegal and carries considerable safety risks.

Legal status varies by country and can change. This is not legal advice.

SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01